Recent approvals and clinical trial results continue to enhance the treatment landscape for patients with non–muscle-invasive and muscle-invasive bladder cancer.

Recent trials have reported advances of chemoradiation strategies in the treatment of locally advanced cervical cancer, which have been incorporated into the NCCN Guidelines^®.

NSCLC is a complex disease with many variables to consider for systemic therapy selection, including the rapidly growing number of predictive biomarkers.

The integration of targeted therapies is revolutionizing the management of primary CNS malignancies. Frequently emerging new data can make it challenging to understand the latest systemic therapy recommendations.

The systemic therapy landscape of hepatocellular cancer (HCC) has evolved in recent years as data has become available about the efficacy of immunotherapy in this disease. It can be challenging for health care professionals to keep up with the latest data.

Due to recent FDA approvals, several types of perioperative systemic therapies are now available for the treatment of resectable non-metastatic non-small cell lung cancer.

Management of Richter transformation (RT) with conventional chemotherapy is largely met with poor responses and short survival.

ALL in the pediatric patient demographic has demonstrated a growing improvement in survival rates over the past five decades. However, challenges in management approaches and prognoses persist.